Ensign Peak Advisors’s ALX Oncology ALXO Stock Holding History

Ensign Peak Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.91M	Buy	+950,550	New	+$1.81M	﹤0.01%	719
2022 Q3	–	Sell	-1,350	Closed	-$11K	–	2311
2022 Q2	$11K	Sell	1,350 -126,082	-99%	-$1.37M	﹤0.01%	2143
2022 Q1	$2.15M	Hold	127,432	–	–	﹤0.01%	852
2021 Q4	$2.74M	Sell	127,432 -218,052	-63%	-$9.41M	0.01%	849
2021 Q3	$25.5M	Sell	345,484 -31,381	-8%	-$2.09M	0.05%	275
2021 Q2	$20.6M	Buy	376,865 +40,566	+12%	+$2.43M	0.04%	313
2021 Q1	$24.8M	Buy	336,299 +309,255	+1,144%	+$24.3M	0.05%	276
2020 Q4	$2.33M	Buy	+27,044	New	+$1.63M	0.01%	972

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Ensign Peak Advisors's ALXO Position: Q1 2026 in Review

Ensign Peak Advisors opened a new position in ALX Oncology (ALXO) in Q1 2026: 950,550 shares worth $1.91M. The stake represents ﹤0.01% of the portfolio and ranks #719 among its holdings. This is a return to the name: Ensign Peak Advisors previously reported a position in ALXO as recently as Q2 2022.

Ensign Peak Advisors first reported a position in ALXO in Q4 2020 and has held it in 8 quarters since. The position peaked at $25.5M in Q3 2021. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Ensign Peak Advisors held 950,550 shares of ALX Oncology worth $1.91M as of Q1 2026.
ALX Oncology was a new Ensign Peak Advisors position in Q1 2026.
ALX Oncology made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #719 holding.
Ensign Peak Advisors first reported a position in ALX Oncology in Q4 2020 and has held it in 8 quarters since.
Ensign Peak Advisors's ALX Oncology position peaked at $25.5M in Q3 2021.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.